AstraZeneca has a deep-rooted heritage in oncology and offers a quickly growing portfolio of medicines with the potential to transform patients' lives. By following the science and championing the development of personalised combinations, AstraZeneca is working to redefine cancer treatment and one day eliminate cancer as a cause of death.
GSK is focused on maximizing patient survival through transformational medicines. GSK’s pipeline is focused on immuno-oncology, cell therapy, cancer epigenetics and synthetic lethality. Our goal is to achieve a sustainable flow of new treatments based on a diversified portfolio of investigational medicines utilizing modalities such as small molecules, antibodies, antibody drug conjugates and cells, either alone or in combination.
Genmab is an international biotechnology company with a core purpose to improve the lives of people with cancer. Founded in 1999, Genmab utilizes its next-generation antibody technologies to create novel therapies. Genmab’s proprietary pipeline consists of modified antibody candidates, including bispecific T-cell engagers and next-generation immune checkpoint modulators, effector function enhanced antibodies and antibody-drug conjugates.
Alkermes is a fully integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on addiction and schizophrenia, and a pipeline of product candidates in development for schizophrenia, bipolar I disorder, neurodegenerative disorders and cancer. Alkermes is headquartered in Dublin, Ireland.